Babak Orandi
Transplant Surgery · New York, NYNPI 1043483191
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,475 of the $10,478 with a category attached, or 80.9%. Boehringer Ingelheim accounts for 91.0% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $8,682, more than ten times the $12 reported in 2020.
Across 25 payments — averaging $419.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$10K
- Novo Nordisk$484
- United Therapeutics Corporation$183
- Intra-sana Laboratories$150
- Lilly USA, LLC$117
- Veloxis Pharmaceuticals, Inc.$12
What the payments were for
- Consulting fees$8,47581%
- Travel & lodging$7677%
- Food & beverage$1,19211%
- Education$440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 10 | $9,533 |
| Novo Nordisk | 8 | $484 |
| United Therapeutics Corporation | 2 | $183 |
| Intra-sana Laboratories | 1 | $150 |
| Lilly USA, LLC | 2 | $117 |
| Veloxis Pharmaceuticals, Inc. | 2 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$359
- Reltone 200 Mg$150
- GLYCATE$150
- Reltone 400 Mg$150
- STEEN Solution$101
- TYVASO$101
How this compares
$10,478 in reported general payments places this provider in the 75th percentile of 72 transplant surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 47 | $56,826 |
| MounjaroTirzepatide | 17 | $28,958 |
| WegovySemaglutide | 15 | $19,765 |
| Naltrexone Hcl | 26 | $778 |
| Metformin Hcl ErMetformin Hcl | 23 | $287 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $484 | $76,59262 claims |
| Lilly USA, LLCMounjaro | $117 | $28,95817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 72 transplant surgery providers in New York.
Other transplant surgery in New York
- Kishore IyerNew York$95K
- Jason HawksworthNew York$91K
- Parissa TabrizianNew York$74K
- Lloyd RatnerNew York$32K
- Hautien LiouNew York$31K
- Karim HalazunNew York$28K
- Myron SchwartzNew York$27K
- Ron ShapiroNew York$16K
- Gabriel GondolesiNew York$15K
- Lewis TepermanNew York$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.